Meet the mom curing her daughter's incurable disease

When Karen Aiach’s infant daughter Ornella was diagnosed with a fatal genetic disorder, she upended her own life to find a cure. Five years after doctors told her Ornella likely wouldn’t live past adolescence, Karen won approval to put the treatment she developed into clinical trials. Her first subject? Ornella.

This is practically unheard of. Karen isn’t a doctor, and had never worked in medicine. The disease Ornella has–called Sanfillipo syndrome–is so rare that almost no one was trying to cure it. But by raising the money and coordinating researchers from across the globe, she was able to develop a revolutionary treatment. And she did it using gene therapy.

“Some people would say, ‘What is she going to do? If no one has done it before, it’s because it cannot be done.” – Karen Aiach

Right now, there are only three gene therapies on the market in the entire world. First developed in 1988, it’s one of the newer and most cutting edge therapy techniques we have. It involves using a virus to replace faulty genetic code with good genetic code.

Lysogene, the company Karen started, has changed Ornella’s and Karen’s lives. And if it passes clinical trial stage, it could change the lives of Sanfilippo sufferers across the globe–and pave the way for a bold new era of medicine.

Related
A dietician explains “Zepbound,” the newest weightloss drug
Zepbound recently joined the list of obesity-fighting drugs administered as injections that has been approved by the FDA.
One-and-done anti-aging treatment “rejuvenates” old mice
CAR-T cells that have been modified to target senescent cells could be a one-and-done anti-aging treatment.
Drinking this foam could boost an experimental cancer therapy
A drinkable foam packed with carbon monoxide molecules appears to boost the cancer-killing effects of autophagy inhibitors.
Deaf boy hears within days of receiving new gene therapy
A gene therapy designed to treat a rare form of genetic deafness has restored hearing in the first patient to receive it.
DeepMind’s AI could accelerate drug discovery
A new study suggests that AlphaFold, DeepMind’s AI tool for predicting protein structures, could be useful for drug discovery after all.
Up Next
Subscribe to Freethink for more great stories